A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment

A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment of Alpha-1 Antitrypsin deficiency–dssociated liver disease with METAVIR stage F2 to F4 fribrosis.

Open

Protocol code: TAK-999-3001
EudraCT code: _
Research group: Liver Diseases
Service: Hepatology
Principal investigator: Pons Delgado, Mònica
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III
Status: Recruiting volunteers